(Reuters) -The U.S. Food and Drug Administration on Wednesday approved Bayer’s drug for patients with a type of lung cancer.
The drug, branded as Hyrnuo, was approved for adults with non-squamous non-small cell lung cancer that has advanced or spread to other parts of the body, as detected by an FDA-approved test, and who have received a prior therapy.
The company did not immediately respond to a Reuters request for comment.
Hyrnuo belongs to a class of drugs that blocks the action of protein kinases that regulate cell growth.
(Reporting by Sriparna Roy in Bengaluru; Editing by Alan Barona)
Brought to you by www.srnnews.com